Nocturnal akathisia in Parkinson's disease: treatment with clozapine.

Abstract

We present the results obtained using low doses of clozapine (mean dose 26.4 mg at bedtime) in the treatment of nocturnal akathisia in nine patients with Parkinson's disease for a mean period of 12.5 months. The results were excellent in all the patients. Furthermore, three patients experienced a remarkable improvement in rest tremor and in five patients the confusional state that accompanied the akathisia also disappeared. No serious side-effects were observed. We believe that clozapine is a very useful drug for the relief of nocturnal akathisia in parkinsonian subjects.

• Authors: G Linazasoro, J F Martí Massó, J A Suárez
• Journal: Movement disorders : official journal of the Movement Disorder Society (Mov Disord) Vol. 8 Issue 2 Pg. 171-4 (Apr 1993) ISSN: 0885-3185 [Print] United States
• PMID: 8474484 (Publication Type: Journal Article)

Chemical References

• Benserazide
• Clozapine
• Carbidopa

Topics

• Adult
• Aged
• Aged, 80 and over
• Benserazide (administration & dosage, adverse effects)
• Carbidopa (administration & dosage, adverse effects)
• Circadian Rhythm (drug effects)
• Clozapine (adverse effects, therapeutic use)
• Confusion (drug therapy)
• Dose-Response Relationship, Drug
• Female
• Humans
• Male
• Middle Aged
• Neurologic Examination (drug effects)
• Parkinson Disease (drug therapy)
• Psychomotor Agitation (drug therapy)
• Sleep Wake Disorders (drug therapy)